Skip to content
Tissue Repair logo — An Australian biopharmaceutical company developing advanced...

Tissue Repair

An Australian biopharmaceutical company developing advanced wound healing products for medical and cosmetic aftercare.

Founded 2012 Australia Australia 12 employees Biopharma, Biotechnology +1

General Information

Company Name Tissue Repair
Founded Year 2012
Location Australia Australia
Employees 12
Industries Biopharma, Biotechnology, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Tissue Repair. To contact Tissue Repair, visit tissuerepair.com.au.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tissue Repair compare?

A PDF of Tissue Repair and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tissue Repair soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Tissue Repair

Tissue Repair Ltd is an Australian biopharmaceutical company founded in 2012. The company focuses on developing advanced wound healing products for chronic wounds. Tissue Repair has created a unique active ingredient designed for wound healing and topical delivery. This ingredient mimics a yeast infection, acting as a decoy cell and stimulating the body’s natural wound repair pathways. The innovative technology not only targets chronic wounds but also holds potential for applications in cosmetic procedures. With a stronghold in Biopharma, Biotechnology, and Pharmaceutical industries, the company's active ingredient offers a platform for developing a range of products across the wound care market. The startup has yet to disclose its last investment details and investors.

Business keywords: Biopharmaceutical, Wound healing, Chronic wounds, Clinical stage, Advanced technology, Topical delivery, Active ingredient, Wound repair pathways, Yeast infection simulation, Cosmetic procedures, Biological pharmaceuticals, Wound care market, Medical research, Pharmaceutical development

No funding data available for Tissue Repair yet.

Tissue Repair Alternatives & Competitors

View All Alternatives
Tissue Repair vs

Start-up Dermatology Company.

Series A
1 employees
Biopharma, Biotechnology
Tissue Repair vs

Specializing in advanced solutions for CKD patients with vitamin D insufficiency and hyperphosphatem...

Series C
Biotechnology, Pharmaceutical
Tissue Repair vs

Advancing the science of chronic pain relief by targeting P2X3 receptors in nerve fibers

Series C
2-10 employees
Biopharma, Biotechnology

FAQ About Tissue Repair

An Australian biopharmaceutical company developing advanced wound healing products for medical and cosmetic aftercare.
Tissue Repair was founded in 2012.
Tissue Repair is headquartered in Australia.
Tissue Repair operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Biopharmaceutical, Wound healing, Chronic wounds and Clinical stage.
Tissue Repair has approximately 12 employees.
Top alternatives and competitors to Tissue Repair include Vicept Therapeutics, Inc, Cytochroma, Afferent Pharmaceuticals, Microbion Corporation, Reviva Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tissue Repair and Vicept Therapeutics, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tissue Repair, https://bouncewatch.com/company/tissue-repair, updated 30 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout